Thanks for the reply. I was just thinking of some of the various possible ways things could play out. Don't see a "winner" take all approach and especially not the first-to-market cannibalizing it. Think it is probably too early to know with any degree of certainty just curious on the feasibility and if an "easier" regiment could potentially lead to patients seeking treatment sooner.
About the PROVE-1 results, I know there are a lot of knoweldgeable posters in this area I am not one! I would just be guessing with little to back it up. If you want a guess I would say 95%, 85% and 75%. I actually would like to see the compound do quite well I think it would be good for all PI's.... Wouldn't mind seeing some management miscue's to delay things though :)
Market Data 
Markets 
AI
